Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 0.82 |
| ▸ | RAB9A | P51151 | 7/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.82 |
| ▸ | GSK3B | P49841 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | GSK3A | P49840 | 2/20 | 0.82 |
| ▸ | HTT | P42858 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.74 |
| ▸ | HPGD | P15428 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16157074 | 0.97 | EGFR (0.94) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16157092 | 0.93 | EGFR (0.88) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16157157 | 0.91 | GSK3B (0.89) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL5024067 | 0.91 | GSK3B (1.00) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16157117 | 0.89 | EGFR (0.80) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16157100 | 0.89 | EGFR (0.80) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16157040 | 0.89 | EGFR (0.80) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL17480620 | 0.89 | EGFR (0.80) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16211143 | 0.89 | EGFR (0.80) | EGFRNPC1RAB9AL3MBTL1GSK3B | |
| SCHEMBL16157046 | 0.89 | EGFR (0.80) | EGFRNPC1RAB9AL3MBTL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013007663-A1 | 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF | Technische Universität Darmstadt (DE) | 2013-01-17 | — | — | WO | claimed |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | MASSACHUSETTS GENERAL HOSPITAL | 2020-05-07 | — | — | US | disclosed |
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| WO-2014165090-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8846661-B2 | Diazahomoadamantane derivatives and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2443122-B1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2013007663-A1 | 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF | Technische Universität Darmstadt (DE) | 2013-01-17 | — | — | WO | disclosed |
| EP-2443122-A1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100324027-A1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010145208-A1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | GOT2, G6PD, FNTB | EGFR 4472/4885NPC1 507/4885RAB9A 3054/4885 |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | EGFR 4472/4885NPC1 507/4885RAB9A 3054/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | EGFR 1984/4885NPC1 902/4885RAB9A 1215/4885 |
| US-20100324027-A1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | DDT, NISCH, OGA | EGFR 3158/4885NPC1 1241/4885RAB9A 2093/4885 |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | EGFR 4472/4885NPC1 507/4885RAB9A 3054/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | EGFR 2513/4885NPC1 303/4885RAB9A 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.